Cytolytic and cytotoxic activity of a human natural killer cell line genetically modified to specifically recognize HER-2/neu overexpressing tumor cells

Immunopharmacology and Immunotoxicology

Volumn 28, Issue 4, 2006, Pages 571-590

  Demirtzoglou, F J ^a,c   Papadopoulos, S ^b   Zografos, G ^b  

^a SAINT SAVVAS HOSPITAL   (Greece)

^b HIPPOKRATION HOSPITAL   (Greece)

^c Cancer Immunology and Immunotherapy Center   (Greece)

Author keywords

Chimeric receptor; HER 2 neu; Immunotherapy; NK92; scFv

Indexed keywords

ANTINEOPLASTIC AGENT; CD3 ANTIGEN; CD8 ANTIGEN; DNA; LYMPHOCYTE ANTIGEN RECEPTOR; NATURAL KILLER CELL 92 EPIDERMAL GROWTH FACTOR RECEPTOR 2 ZETA; PEPTIDE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL BASED GENE THERAPY; CELL SURFACE; CHIMERA; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DNA MODIFICATION; GENE OVEREXPRESSION; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR RECOGNITION; MOUSE; NATURAL KILLER T CELL; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; RECEPTOR GENE; TUMOR CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; EXOTOXINS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; KILLER CELLS, NATURAL; MICE; MICE, SCID; NEOPLASMS; ORGANISMS, GENETICALLY MODIFIED; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC;

EID: 33845908470     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.1080/08923970601066971     Document Type: Article

References (49)

1. Moritz, D.; Wels, W.; Mattern, J.; Grower, B. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc. natl. acad. sci USA. 1994, 91 (10), 4318-4322.
2. Altenschmidt, U.; Klundt, E.; Grower, B. Adoptive transfer of in vitro-targeted, activated lymphocytes results in total tumor regression. J. Immunol. 1997, 159 (11), 5509-5515.
3. Brocker, T.; Karjalainen, K. Adoptive tumor immunity mediated by lymphocytes bearing modified antigen-specific receptors. Adv Immunol. 1997, 68, 257-269.
4. Eshhar, Z.; Waks, T.; Bendavid, A.; Schindler, D.G. Functional expression of chimeric receptor genes in human T cells. J Immunol Meth. 2001, 248, 67-76.
5. Eshhar, Z.; Waks, T.; Gross, G.; Schindler, D.G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA. 1993, 90, 720-724.
6. Hwu, P.; Yang, J.C.; Lowherd, R.; Treisman, J.; Shafer, G.E.; Eshhar, Z.; Rosenberg, S.A. In vivo antitumor activity of T cells redirected with chimeric antibody/T- cell receptor genes. Cancer Res. 1995, 55 (15), 3369-3373.
7. Niederman, T.M.J.; Ghogawala, Z.; Carter, B.S.; Tompkins, H.S.; Russell, M.M.; Mulligan, R.C. Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc Natl Acad Sci USA. 2002, 99 (10), 7009-7014.
8. Haynes, N.M.; Snook, M.B.; Tragani, J.A.; Cerruti, L.; Jane, S.M.; Smyth, M.J.; Darcy, D.K. Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-ζ vs. Fcε RI-γ. J Immunol. 2001, 166 (1), 182-187.
9. Maher, J.; Brentjens, R.J.; Gunset, G.; Riviere, I.; Sadelain, M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nat Biotech. 2002, 20 (1), 70-75.
10. Weijtens, M.E.M.;Willemsen, R.A.; Valerio, D.; Stam, K.; Bolhuis, R.L.H. Single chain Ig/γ gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J Immunol. 1996, 157 (2), 836-843.
11. Roberts, M.R.; Looke, K.S.; Tran, A.-C.; Smith, K.A.; Lin, W.L.; Wang, M.; Dull, T.J.; Farson, D.; Zsebo, K.M.; Finer, M.H. Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing ζ or γ signaling domains. J Immunol. 1998, 161 (1), 375-384.
12. Mamalaki, A.; Gritzapis, A.D.; Kretsovali, A.; Belimezi, M.; Papamatheakis, J.; Perez, S.A.; Papamichail, M.; Baxevanis, C.N. In vitro and in vivo antitumor activity of a mouse CTL hybridoma expressing bearing the single chain Fv from HER-2/neu- specific antibody and the gamma-chain from Fc(epsilon) RI. Cancer Immunol Immunother. 2003, 52 (8), 513-522.
13. Gritzapis, A.D.; Mamalaki, A.; Kretsovali, A.; Papamatheakis, J.; Belimezi, M.; Perez, S.A.; Baxevanis, C.N.; Papamichail, M. Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells. Br J Cancer. 2003, 88 (8), 1292-1300.
14. Baxevanis, C.N.; Papamichail, M.; Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genes. Cancer Immunol Immunother. 2004, 53 (10), 893-903.
15. Slamon, D.J.; Godolphin, W.; Jones, L.A.; Holt, J.A.; Wong, S.G.; Keith, D.E.; Levin, W.J.; Stuart, S.G.; Udove, J.; Ullrich, A. Press, MF. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244 (4905), 707-712.
16. Yamanaka, Y.; Friess, H.; Kobrin, M.S.; Buchler, M.; Kunz, J.; Beger, H.G.; Korc, M.; Overexpression of HER-2/neu protooncogene in human pancreatic carcinoma. Hum Pathol. 1993, 24, 1127-1134.
17. Maxwell-Armstrong, C.A.; Durrant, L.G.; Scholefield, J.H. Colorectal cancer vaccines. Br J Surg. 1998, 85 (2), 149-154.
18. Pauletti, G.; Godolphin, W. Press, M.F.; Slamon, D.J. Detection and quantitation of HER-2/neu gene amplification in human breast cancer and archival material using fluorescence in situ hybridization. Oncogene. 1996, 13, 63-72.
19. Baxevanis, C.N.; Sotiropoulou, P.A.; Sotiriadou, N.N.; Papamichail, M. Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy. Cancer Immunol Immunother. 2004, 53 (3), 116-175.
20. Gritzapis, A.D.; Mahaira, L.G.; Perez, S.A.; Cacoullos, N.T.; Papamichail, M.; Baxevanis, C.N. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo. Cancer Res. 2006, 66 (10), 5452-5460.
21. Baxevanis, C.N.; Sotiriadou, N.N.; Gritzapis, A.D.; Sotiropoulou, P.A.; Perez, S.A.; Cacoullos, N.T.; Papamichail, M. Immunogeneic HER-2/neu peptides as tumor vaccines. Cancer Immunol Immunother. 2006, 55 (1), 85-95.
22. Gritzapis, A.D.; Perez, S.A.; Baxevanis, C.N.; Papamichail, M. Pooled peptides from HER-2/neu-overexpressing primary ovarian tumours induce CTL with potent antitymor responses in vitro and in vivo. Br J Cancer. 2005, 92 (1), 72-79.
23. Yoshino, I.M.; Goedegebuure, P.S.; Peoples, G.E.; Parish, A.S.; DiMaio, J.M.; Lyerly, H.K.; Gazdar, A.F.; Eberlein, T.J. HER-2/neu-derived peptides are shared antigens among non-small cell lung cancer and ovarian cancer. Cancer Res. 1994, 54 (13), 3387-3390.
24. Fisk, B.; Blevins, T.L.; Wharton, J.T.; Ioannides, C.G. Indentification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med. 1995, 181 (6), 2109-2117.
25. Peiper, M.; Goedegebuure, R.S.; Lineham, D.C.; Ganguly, E.; Douville, C.C.; Eberlein, T.J. The HER-2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes. Eur J Immunol. 1997, 27, 1117-1123.
26. Brossart, P.; Stuhler, G.; Flad, T.; Stevanovic, S.; Rammensee, H.-G.; Kanz, L.; Brugger, W. Her-2/neu-derived peptides are tumor associated antigens expressed by human renal cell and colon carcinoma cell lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res. 1998, 58 (4), 732-736.
27. Sotiriadou, R.; Perez, S.A.; Gritzapis, A.D.; Sotiropoulou, P.A.; Echner, A.; Heinzel, S.; Mamalaki, A.; Pawelec, G.; Voelter, W.; Baxevanis, C.N.; Papamichail, M. Peptide HER2 (776-788) represents a naturally processed broad MHC class II-restricted T cell epitope. Brit J Cancer. 2001, 85 (10), 1527-1534.
28. Baxevanis, C.N.; Gritzapis, A.D.; Tsitsilonis, O.E.; Katsoulas, H.; Papamichail, M. HER-2/ neu-derived peptide epitopes are also recognized by cytotoxic CD3+ CD56+ (natural killer T) lymphocytes. Int J Cancer. 2002, 98 (6), 864-872.
29. Perez, S.A.; Sotiropoulou, P.A.; Sotiriadou, N.N.; Mammalaki, A.; Gritzapis, A.D.; Echner, H.; Voelter, W.; Pawelec, G.; Papamichail, M.; Baxevanis, C.N. HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4+ T cell clones. Cancer Immunol Immunother. 2002, 50 (11), 615-624.
30. Baxevanis, C.N.; Sotiriadou, N.N.; Gritzapis, A.D.; Sotiropoulou, P.A.; Perez, S.A.; Cacoullos, N.T.; Papamichail, M. Immunogenic HER-2/neu peptides as tumor vaccines. Cancer Immunol Immunother. 2006, 55 (1), 89-95.
31. Gritzapis, A.D.; Sotiriadou, N.N.; Papamichail, M.; Baxevanis, C.N. Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from elutes of human primary breast and ovarian tumors. Cancer Immunol Immunother. 2004, 53 (11), 1027-1040.
32. Sotiropoulou, P.A.; Perez, S.A.; Voelter, V.; Echner, H.; Missitzis, I.; Tsavaris, N.B.; Papamichail, M.; Baxevanis, C.N. Natural CD8+ T-cell response against MHC class I epitopes of the HER-2/neu oncoprotein in patients with epithelial tumors. Cancer Immunol Immunother. 2003, 52 (12), 771-779.
33. Sotiropoulou, P.A.; Perez, S.A.; Iliopoulou, E.G.; Missitzis, I.; Voelter, V.; Echner, H.; Baxevanis, C.N.; Papamichail, M. Cytotoxic T-cell precursor frequencies to HER-2 (369-377) in patients with HER-2/neu -positive epithelial tumors. Br J Cancer. 2000, 89 (6), 1055-1061.
34. Disis, M.L.; Calenoff, E.; McLaughlin, G.; Murphy, A.E.; Chen, W.; Grower, B.; Jeschke, M.; Lyndon, N.; McGlynn, E.; Livingston, R.B.; Moe, R.; Cheever, M.A. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 1994, 54 (1), 16-20.
35. Disis, M.L.; Smith, J.W.; Murphy, A.E.; Chen, W.; Cheever, M.A. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res. 1994, 54 (4), 1071-1076.
36. Knutson, K.L.; Almand, B.; Mankoff, D.A.; Schiffman, K.; Disis, M.L. Adoptive T-cell therapy for the treatment of solid tumours. Expert Opin Biol Ther. 2002, 2 (1), 55-66.
37. Knutson, K.L.; Schiffman, K.; Disis, M.L. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest. 2001, 107 (5), 553-554.
38. Kobayashi, H.; Wood, M.; Song, Y.; Appella, E.; Celis, E. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res. 2000, 60 (18), 5228-5236.
39. Rosenberg, S.A. The immunotherapy and gene therapy of cancer. J Clin Oncol. 1992, 10, 180-199.
40. Pawelec, C.; Zeuthen, J.; Kiessling, R. Escape from host-antitumor immunity. Crit Rev Oncog. 1997, 8 (2-3), 111-141.
41. Uherek, C.; Tonn, T.; Uherek, B.; Becker, S.; Schnierle, B.; Klingermann, H.-G.; Wels, W. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood. 2002, 100 (4), 1265-1273.
42. Evan, G.I.; Lewis, G.K.; Ramsay, G.; Bishop, J.M. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol Cell Biol. 1985, 5, 3610-3616.
43. Harwerth, I.M.; Wels, W.; Marte, B.M.; Hynest, N.E. Monoclonal Antibodies against the Extracellular Domain of the erbB-2 Receptor Function as Partial Ligand Agonists. J Biol Chem. 1992, 267 (21), 15160-15167.
44. Perez, S.A.; Mahaira, L.G.; Demirtzoglou, F.J.; Sotiropoulou, P.A.; Ioannidis, P.; Iliopoulou, E.G.;Gritzapis, A.D.; Sotiriadou, N.N.; Baxevanis, C.N.; Papamichail, M. A potential role for hydrocortisone in the positive regulation of IL-15-activated NK-cell proliferation and survival. Blood. 2005, 106 (1), 158-166.
45. Tsantili, P.; Tzartos, S.; Mamalaki, A. (1999) High affinity scFv antibody fragments protecting he human nicotinic acetylcholine receptor. J Neuroimmunol. 1999, 94 (1-2), 15-27.
46. Laemmli, U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970, 227 (5259), 680-685.
47. Hoogenboom, H.R.; Griffiths, A.D.; Johnson, K.S.; Chiswell, D.J.; Hudson, P.; Winter, G. Multi-Subunit Proteins on the Surface of Filamentous Phage Methodologies for Displaying Antibody (Fab) Heavy and Light Chains. Nucleic Acids Res. 1991, 19 (15), 4133-4137.
48. Kauraniemi, P.; Hautaniemi, S.; Autio, R.; Astola, J.; Monni, O.; Elkahloun, A.; Kallioniemi, A. Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines. Oncogene. 2004, 23 (4), 1010-1013.
49. Workman, P.; Twentyman, P.; Balwill, A.; Chaplin, D.; Double, J.; Embleton, J.; Newell, D.; Raymond, R.; Stables, J.; Stephens, T.; Wallace, J. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). Br J Cancer. 1998, 77, 1-10.